Regulatory Affairs in India

A pharma company finishes Phase-3 and wants to sell the drug. You compile the dossier — chemistry, manufacturing, controls, preclinical, clinical, labelling — into the eCTD format, file it on CDSCO SUGAM (India), FDA ESG (US) or EMA CESP (EU), and own every back-and-forth with the regulator until approval. Same job for medical devices under MDR/IVDR. One missed module, one wrong label claim, and the launch slips by a year.

India is the world's largest generics exporter and a fast-growing devices market. Every export filing, every label change, every post-approval variation needs an RA owner. India also runs RA ops for ~55% of MNC pharma global filings (Freyr alone ships 10,000+ submissions/yr).

Global RA outsourcing market: ~$8B in 2025, India captures ~40% of execution work (NASSCOM + IQVIA).

Who fits: B.Pharm, M.Pharm (Reg. Affairs preferred), Pharm.D, M.Sc Life Sciences. Devices RA also takes B.Tech Biomedical. Strong written English non-negotiable — you draft for regulators.

1. Step 1Y0

   RA Associate (L1)

   ₹3.8 – 6.5 LPA

   Unlock: Trained on eCTD + first 5 module-3 sections

2. Step 2Y2

   RA Executive (CMC or Labelling)

   ₹6.5 – 11 LPA

   Unlock: Owns 1 product end-to-end + Veeva Vault RIM cert

3. Step 3Y5

   RA Manager / Strategist

   ₹12 – 18 LPA

   Unlock: RAC + first regulator meeting representation

4. Step 4Y8+

   Global RA Lead / RA Head

   ₹22 – 35 LPA

   Unlock: Multi-market portfolio + audit + board reporting

• RA Associate (L1) — dossier compilation
• RA Executive — CMC / labelling
• RA Publisher (eCTD)
• Regulatory Strategist
• RA Manager (Devices / Drugs)
• Global RA Lead

• RAC (Regulatory Affairs Certification, RAPS)

  +₹1.5–2L at offer; near-mandatory for senior RA in MNCs

• TOPRA MSc Regulatory Affairs

  Promotion to Strategist by Y4; UK/EU mobility

• Veeva Vault RIM Administrator

  +₹1L; gates publishing-team roles

• RA vs PV — which pays better long-term?

  RA. PV starts ₹0.3-0.5 LPA higher at L1, but RA overtakes by Y3 and at Y8+ RA pays 30-50% more (₹22-35 vs ₹15-26). Reason: RA owns market access; PV is monitoring.

• CDSCO vs USFDA filings — which to learn first?

  USFDA. India RA hiring is dominated by US-bound generics (ANDA filings). CDSCO knowledge is layered on later. EU/EMA is the third skill.

• Does RAC certification really pay?

  Yes. RAC adds ₹1.5-2L immediately at offer in MNCs and is near-mandatory for the Manager step (Y5). It also unlocks UAE/UK/EU roles.

• Devices RA or Drugs RA — different careers?

  Yes. Devices RA (under MDR/IVDR + ISO 13485) pays slightly higher and the talent pool is smaller. Drugs RA has 10x more openings. Pick devices if you have B.Tech Biomedical or device industry exposure.

• Can a fresher get an RA job without M.Pharm?

  Yes — B.Pharm + a structured RA course (eCTD + ICH + 1 mock dossier) lands L1 offers at Freyr, Navitas, ProPharma at ₹3.8-6 LPA. M.Pharm RA mainly speeds Y3 promotion.

• Is RA a good abroad route?

  One of the best in healthcare. UK, Ireland, UAE and Singapore all run structural RA shortages. RAC + 4 yrs exp + visa is the formula.